摘要
通过对埃洛石纳米管(HNTs)表面用生物活性分子进行修饰,使其具备靶向特性,探讨其负载抗癌药物及其靶向控制释放给药作用效果。首先对HNTs表面进行氨基化修饰,再偶联肾癌标志物斑点型POZ蛋白(speckle-type POZ protein,SPOP)抗体,构建HNTs-SPOPab靶向载体,采用扫描电镜、透射电镜、傅立叶变换红外光谱、X射线衍射图谱等对其进行形态和性能表征;然后在HNTs-SPOPab管腔内载入抗肾癌药物索拉菲尼(sorafenib,SOR),与肾癌细胞A498共培养24h,通过流式细胞仪检测证实有抑制肾癌细胞生长增殖的作用。另外,还在HNTs-SPOPab管腔内载入了另一种抗肺癌药物吉西他滨(gemcitabine,GEM),与肺癌细胞A549(无SPOP特异抗原)共培养24h,通过Edu掺入试验,观察其对肺癌细胞增殖的抑制效果。HNTs-SPOPab作为药物载体具有相对稳定的结构和功能。流式结果显示HNTs-SPOPab负载索拉菲尼对肾癌细胞周期具有更强的抑制作用,抑制百分率相对于无药物载体的原药直接给药组提高了(16.12±0.45)%。Edu掺入实验结果表明,HNTsSPOPab负载GEM对肺癌细胞抑制作用虽然相对于直接给药组略高,荧光抑制比率HNTs-SPOPab-GEM:(94.12±3.91)%>GEM:(87.83±1.42)%,但两组间无显著性差异。HNTs-SPOPab作为一种新的纳米靶向药物载体,具有靶向肾癌细胞给药传递的潜能。
To research the targeting effect of HNTs loaded anti-cancer drug with cancer cells,the surface of HNTs with bioactive molecules was modified to make it with features of targeting carrier.Firstly,the surface of HNTs with amination was modified.Then the speckle-type POZ protein（SPOP）antibody was coupled to the surface of HNTs to establish the HNTs-SPOPab drug carrier and its morphology and properties were characterized by SEM,TEM,FT-IR and XRD,respectively.Secondly,the sorafenib（SOR）was loaded into HNTsSPOPab and the product was cocultured with A498 cells for 24 h.The inhibitory effect of HNTs-SPOPab loaded with drug was dected by FACS.Besides,gemcitabine（GEM）was loaded into HNTs to compare the inhibitory effect on A549 cells（without SPOP specific antigen）by Edu test.The results showed that HNTs-SPOPab has features of stable structure and characters.The results of FACS suggested that HNTs-SPOPabloaded with drug has more significant inhibitory effect to A498 cells.The percentage of suppression of HNTs-SPOPabloaded drug is（16.12±0.45）% higher than free drug directly.The results of Edu test showed that the HNTs-SPOPabloaded GEM has no significant difference with free drug to A549 cells.The suppression fluorescence ratio of HNTsSPOPab-GEM is（94.12±3.91）%,which is higher than that of GEM（87.83±1.42）%.HNTs-SPOPab may be a potential promising targeting nanocarrier in the application of treatment in renal cancer.
出处
《功能材料》
EI
CAS
CSCD
北大核心
2018年第1期1121-1126,共6页
Journal of Functional Materials
基金
国家自然科学基金资助项目(81471789)
